





Instructions to Authors

### Aims and Scope

Antiviral Research publishes full-length original articles, short definitive papers and review articles (one per issue), pertaining to the effective control of virus infections in animals and man as well as in plants or lower organisms.

Its scope encompasses: – the mechanism of natural and acquired host resistance against virus infections, including aspecific cellular resistance; interferons; cellular and humoral immunity in virus infections; chemotherapeutics which influence host resistance; – the development of new vaccines or novel forms of serotherapy against viral diseases, including virological characterization of vaccine strains or vaccine preparations; preparation and characterization of antiviral immunoglobulins; safety and efficiency assessment; field trials; – the development of new antiviral chemotherapeutics, including chemistry; in vitro activity; mechanism of action; activity in animal model systems; clinical trials.

Submission of a paper to an Elsevier Virology Journal implies that it has not previously been published (except in abstract form) and that it is not being submitted for publication elsewhere. The authors are requested to transfer their copyright to the Publisher, to ensure the widest possible disemination of information. Papers and original figures should be submitted together with three copies accompanied by a letter of transmittal to (one of) the Editor(s)-in-Chief.

#### **Editors-in-Chief**

**Erik De Clercq,** Rega Institute, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.

**Earl R. Kern** and **Richard J. Whitley**, The University of Alabama at Birmingham, Antiviral Research Editorial Office, 309 Bevill Biomedical Research Building, 845 19th Street South, Birmingham, AL 35294-2170, USA.

### **Associate Editor for Reviews**

**George J. Galasso**, National Institutes of Health (ret.), Health Sciences Consultant, 636 Crocus Drive, Rockville, MD 20850-2045, USA.

# **Conflict of Interest Statement**

Articles published in *Antiviral Research* are expected to be free of any real or apparent conflict of interest. Therefore, any information about the authors' professional and financial

holdings which may be perceived to have biased the results described should be disclosed at the time of submission of the manuscript. The information shall be held in confidence by the Editor, to whom the manuscript was submitted, during the review process. Prior to publication of the article, the Editor will discuss any perceived conflict of interest with the appropriate authors and the method of disclosure to the reader will be determined.

Since review articles entail the selection and interpretation of already published material, the authors of Reviews should not have a financial interest in a company (or its competitor) which makes a product that is discussed in the Review.

**Submission of manuscripts.** The preferred medium of final submission to the accepting Editor is on disk with the accompanying reviewed and revised manuscript (see 'Electronic manuscripts' below). Submitted materials will not be returned to authors unless specifically requested.

**Manuscripts,** in English, should be typed on one side of the paper only with double spacing and wide margins and should have a separate title page bearing author(s) names and affiliations as well as a full postal address, fax and e-mail for immediate enquiry.

**Full-length papers** (Research Articles) should generally not exceed 25 typewritten pages and should be devided into Summary (on a separate sheet and not exceeding 200 words, followed by 3–6 key words), Introduction, Materials and Methods, Results, and Discussion.

**Short Communications** typically should not exceed 1500 words or equivalent space including figures and tables and should not be divided into sections, i.e., Introduction, Materials and Methods, etc. but should have a brief Summary, 3–6 keywords and a full reference list. These must be brief definitive reports, not preliminary findings.

**Review articles** will be published following invitation from the Associate Editor for Reviews.

**Electronic manuscripts:** The **preferred** medium of final submission to the accepting editor is on disk with accompanying reviewed and revised manuscript. Electronic

manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a  $3\frac{1}{2}$  inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter '1' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter  $\alpha$ ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files, 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one final printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

**Tables** should be typed double-spaced on separate sheets, numbered consecutively with Arabic numerals, and only contain horizontal lines. A short descriptive title should appear above each table, with possible legend and footnotes (identified with a, b, c, etc.) below.

**Illustrations.** All illustrations must be submitted in triplicate and reach the editor in a form and condition suitable for reproduction. The illustrations must bear the author's name and be numbered in Arabic numerals according to the sequence of their appearance in the text, where they are to be referred to as Fig. 1, Figs. 2-4 etc. Line drawings should be in black ink on drawing or tracing paper. Lettering should be clear and of adequate size to be legible after reduction. Labelling of professional standard is preferable but, if this is not possible, lettering should be done in fine pencil.

Photographs, electron micrographs, etc., should be supplied as clear black and white prints on glossy paper, and have as much contrast as possible. The degree of reduction will be determined by the Publisher. If figures are not to be reduced, their format should not exceed 7.5 or 16 cm width (single or double column) and 17.5 cm depth. (Further instructions may be found on p. 6 of the booklet Information for Contributors 10

Biochemica et Biophysica Acta, which is available free of charge from: BBA Editorial Secretariat, P.O. Box 521, 1000 AN Amsterdam, The Netherlands.) Reproduction in colour will have to be approved by the Editor(s) and Publisher. The extra cost of colour reproduction will be charged to the author(s). Each illustration must have a legend, which should be typed with double spacing on a separate page and begin with the number of the illustration it refers to.

**Amino acid sequences, gene maps, etc.,** should be submitted as figures.

References should be assembled in alphabetical order on a separate sheet. In the text they should be referred to by name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a,b,c. etc., placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. Literature references must consist of names and initials of all authors, year, title of paper referred to, abbreviated title of periodical, volume number and first and last page numbers of the paper. Periodicals, books and multi-author books should accord with the following examples:

Groen, W.S. and Shaw, R.D. 1992. Psoralen preparation of antigenically intact noninfectious rotavirus particles. J. Viral. Methods 38, 92–102.

Howard, C.R. and Zuckerman, A.J. 1986. Aranaviruses, Elsevier, Amsterdam.

Clerci, M. and Shearer, G.M. 1992. The use of vitro T cell immune function to monitor the course of HIV infection. In: Janossy, G., Autran, B., Miedema, F. (Eds.), Immunodefeciency in HIV infection and AIDS. Karger, Basel, pp. 64–75.

Abbreviations of journal titles should conform to those adopted by List of Serial Title Word Abbreviations (available from the International Serials Data System, 20 rue Bachaumont, 75002 Paris, France. ISBN 2-904939-02-8). Please note that the responsibility for the accuracy and completeness of literature references lies solely with the author(s).

**Virus nomenclature:** Authors are requested to follow the guidelines of the International Committee on Taxonomy of Viruses (ICTV), as mentioned in Vol. 29 (1996) pp. 1–2. The complete report of the ICTV (The Classification and Nomenclature of Viruses: Sixth Report of the ICTV, Murphy, F.A. et al., 1995) is available from Springer-Verlag.

**Proofs** will be sent to the first-named author of an article, unless an alternative is requested on the title page of the manuscript. They should be checked carefully and returned by airmail within 2 days of receipt. Only printer's errors may be corrected: **no changes in or additions to the edited manuscript will be allowed at this stage.** The Publisher will proceed if proofs are not received on time.

Instructions to Authors

## **Author enquiries**

Authors can keep a track on the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript's status, by using the "Track a Paper" feature of Elsevier's Author Gateway (http://www.authors.elsevier.com)

Full details for the electronic submission of artwork can be obtained from http://www.elsevier.com/locate/authorartwork/

Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

vii

Page charges will not be made.

**Reprints** may be ordered by filling in and returning to the Publishers the order form sent to the authors; per contribution 25 reprints will be made available free of charge.